Diabetes

 

Abatacept Lowers Diabetes Risk in RA

April 23, 2020

Abatacept (Orencia, Bristol Myers Squibb), a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis and juvenile idiopathic arthritis, appears to lower the risk of diabetes mellitus in patients with rheumatoid arthritis who are receiving biologic or targeted synthetic DMARDs.

Anakinra Bests TNF Inhibitors in RA Patients with Type 2 Diabetes

October 18, 2019

IL-1 inhibition with anakinra was more effective than TNFi treatment for improving glycemic and inflammatory parameters in patients with rheumatoid arthritis and type 2 diabetes, say researchers writing in PLOS Medicine last month.

DMARDs Reduce Diabetes Risk in RA and Psoriasis

July 28, 2011

In patients who have rheumatoid arthritis (RA) or psoriasis, there is a reduced risk of diabetes mellitus (DM) with the use of a tumor necrosis factor α (TNF-α)inhibitor or hydroxychloroquine (HCQ), but not with methotrexate (MTX), compared with other nonbiologic disease-modifying antirheumatic drugs (DMARDs). Evidence suggests a possible role for DMARDs and immunosuppression in DM prevention

New Diabetic Nerve Pain Treatment Guideline

July 08, 2011

A new guideline on the most effective treatments for patients with diabetic nerve pain-The Evidence Based Guideline: Treatment of Painful Diabetic Neuropathy-was released by the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in collaboration with the American Association of Neuromuscular and Electro-diagnostic Medicine and the American Academy of Neurology

New diabetes management guidelines feature exercise

January 28, 2011

Regular physical activity may help persons prevent or manage type 2 diabetes mellitus (T2DM), improve a person’s overall health, and boost his or her quality of life, according to new guidelines issued jointly by the American College of Sports Medicine (ACSM) and the American Diabetes Association.